Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Fine-Tuning TLR-7-Based Therapy for Functional HBV Cure.

Bertoletti A, Le Bert N.

Hepatol Commun. 2019 Oct 1;3(10):1289-1292. doi: 10.1002/hep4.1420. eCollection 2019 Oct.

2.

Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming.

Bénéchet AP, De Simone G, Di Lucia P, Cilenti F, Barbiera G, Le Bert N, Fumagalli V, Lusito E, Moalli F, Bianchessi V, Andreata F, Zordan P, Bono E, Giustini L, Bonilla WV, Bleriot C, Kunasegaran K, Gonzalez-Aseguinolaza G, Pinschewer DD, Kennedy PTF, Naldini L, Kuka M, Ginhoux F, Cantore A, Bertoletti A, Ostuni R, Guidotti LG, Iannacone M.

Nature. 2019 Oct 2. doi: 10.1038/s41586-019-1620-6. [Epub ahead of print]

PMID:
31582858
3.

Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B.

Le Bert N, Salimzadeh L, Gill US, Dutertre CA, Facchetti F, Tan A, Hung M, Novikov N, Lampertico P, Fletcher SP, Kennedy PTF, Bertoletti A.

J Hepatol. 2019 Jul 23. pii: S0168-8278(19)30424-6. doi: 10.1016/j.jhep.2019.07.015. [Epub ahead of print]

PMID:
31348999
4.

Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy.

Tan AT, Yang N, Lee Krishnamoorthy T, Oei V, Chua A, Zhao X, Tan HS, Chia A, Le Bert N, Low D, Tan HK, Kumar R, Irani FG, Ho ZZ, Zhang Q, Guccione E, Wai LE, Koh S, Hwang W, Chow WC, Bertoletti A.

Gastroenterology. 2019 May;156(6):1862-1876.e9. doi: 10.1053/j.gastro.2019.01.251. Epub 2019 Jan 31.

5.

PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection.

Salimzadeh L, Le Bert N, Dutertre CA, Gill US, Newell EW, Frey C, Hung M, Novikov N, Fletcher S, Kennedy PT, Bertoletti A.

J Clin Invest. 2018 Oct 1;128(10):4573-4587. doi: 10.1172/JCI121957. Epub 2018 Aug 7.

6.

Immunotherapy for Chronic Hepatitis B Virus Infection.

Bertoletti A, Le Bert N.

Gut Liver. 2018 Sep 15;12(5):497-507. doi: 10.5009/gnl17233. Review.

7.

Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation.

Rivino L, Le Bert N, Gill US, Kunasegaran K, Cheng Y, Tan DZ, Becht E, Hansi NK, Foster GR, Su TH, Tseng TC, Lim SG, Kao JH, Newell EW, Kennedy PT, Bertoletti A.

J Clin Invest. 2018 Feb 1;128(2):668-681. doi: 10.1172/JCI92812. Epub 2018 Jan 8.

8.

Genome-derived cytosolic DNA mediates type I interferon-dependent rejection of B cell lymphoma cells.

Shen YJ, Le Bert N, Chitre AA, Koo CX, Nga XH, Ho SS, Khatoo M, Tan NY, Ishii KJ, Gasser S.

Cell Rep. 2015 Apr 21;11(3):460-73. doi: 10.1016/j.celrep.2015.03.041. Epub 2015 Apr 9.

9.

STING-dependent cytosolic DNA sensor pathways regulate NKG2D ligand expression.

Le Bert N, Lam AR, Ho SS, Shen YJ, Liu MM, Gasser S.

Oncoimmunology. 2014 Jun 25;3:e29259. eCollection 2014.

10.

Synergistic anticancer effects of Pam3CSK4 and Ara-C on B-cell lymphoma cells.

Lee SK, Chwee JY, Ma CA, Le Bert N, Huang CW, Gasser S.

Clin Cancer Res. 2014 Jul 1;20(13):3485-95. doi: 10.1158/1078-0432.CCR-13-2522. Epub 2014 May 5.

11.

Advances in NKG2D ligand recognition and responses by NK cells.

Le Bert N, Gasser S.

Immunol Cell Biol. 2014 Mar;92(3):230-6. doi: 10.1038/icb.2013.111. Epub 2014 Jan 21. Review.

PMID:
24445601
12.

Regulation of self-ligands for activating natural killer cell receptors.

Lam RA, Chwee JY, Le Bert N, Sauer M, Pogge von Strandmann E, Gasser S.

Ann Med. 2013 Jun;45(4):384-94. doi: 10.3109/07853890.2013.792495. Epub 2013 May 23. Review.

PMID:
23701136
13.

DC priming by M. vaccae inhibits Th2 responses in contrast to specific TLR2 priming and is associated with selective activation of the CREB pathway.

Le Bert N, Chain BM, Rook G, Noursadeghi M.

PLoS One. 2011 Apr 1;6(4):e18346. doi: 10.1371/journal.pone.0018346.

Supplemental Content

Loading ...
Support Center